Recently, Dicerna Pharmaceuticals (DRNA) announced a partnership with Eli Lilly (LLY) which amounts to an upfront payment and an equity stake. This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Alexion Pharmaceuticals (ALXN) as well. With the two latest validations of Dicerna's platform, it is looking more and more that big pharmaceuticals are betting big on RNA interference as a disruptive type of technology that may offer a promising future for treating diseases. Based on